Arbutus Biopharma : Corporate Presentation - January 2022

Corporate Presentation

January 24, 2022

NASDAQ: ABUS

www.arbutusbio.com

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: the potential market opportunity for HBV; Arbutus' ability to meet a significant unmet medical need; the sufficiency of Arbutus' cash and cash equivalents for the anticipated durations; the expected cost, timing and results of Arbutus' clinical development plans and clinical trials, including its clinical collaborations with third parties; the potential for Arbutus' product candidates to achieve their desired or anticipated outcomes; Arbutus' expectations regarding the timing and clinical development of Arbutus' product candidates, including its articulated clinical objectives; the timeline to a combination cure for HBV; Arbutus' coronavirus strategy; Arbutus' expectations regarding its technology licensed to third parties; the expected timing and payments associated with strategic and/or licensing agreements; and other statements relating to Arbutus' future operations, future financial performance, future financial condition, prospects or other future events.

With respect to the forward-looking statements contained in this presentation, Arbutus has made numerous assumptions regarding, among other things: the timely receipt of expected payments; the effectiveness and timeliness of preclinical studies and clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the continued demand for Arbutus' assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies including uncertainties and contingencies related to the ongoing COVID-19 pandemic. Forward-looking statements herein involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others: anticipated pre-clinical and clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; changes in Arbutus' strategy regarding its product candidates and clinical development activities; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus' products; economic and market conditions may worsen; market shifts may require a change in strategic focus; the parties may never realize the expected benefits of the collaborations; and the ongoing COVID-19 pandemic could significantly disrupt Arbutus' clinical development programs. A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus' Annual Report on Form 10-K, Quarterly Report on Form 10-Q and Arbutus' periodic disclosure filings which are available at www.sec.gov and at www.sedar.com. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

NASDAQ: ABUS	2
www.arbutusbio.com

Investment Highlights

Significant

Unmet

Medical

Need in HBV

Global HBV prevalence double that of HCV, potential for larger market opportunity

Goal of HBV

Functional

Cure

Undetectable HBV

DNA and HBsAg

delivered through

finite duration

treatment with a combination of drugs with different modes of action

Broad

HBV

Portfolio

HBV compounds

include:

RNAi

Capsid Inhibitors

PD-L1 Inhibitors

HBV RNA

Destabilizer

	Team with
Coronavirus	Antiviral	16 %
Research	Expertise &	Ownership in
Initiative	Proven Track	Genevant
	Record
Focused on	Extensive	Rights to potential
direct acting	knowledge gained	future royalties
antivirals	from HIV and HCV	and sublicense
targeting the	success being	revenues for
viral	applied to	patented
polymerase	HBV and	LNP Technology
and protease	Coronaviruses

NASDAQ: ABUS		3
www.arbutusbio.com	HCV: Hepatitis C Virus | HIV Human Immunodeficiency Virus

Proven

Leadership

Team

William H. Collier		Michael J. Sofia, PhD		Gaston Picchio, PhD
President and CEO		Chief Scientific Officer		Chief Development Officer

Successful track records in the discovery, development, and commercialization of multiple antivirals including sofosbuvir, etravirine, rilpivirine, telaprevir and simeprevir

David C. Hastings		Elizabeth Howard, PhD, JD		Michael J. McElhaugh
Chief Financial Officer		EVP, General Counsel and		Chief Business Officer
		Chief Compliance Officer

NASDAQ: ABUS	4
www.arbutusbio.com

Pipeline

RNAi Therapeutic

AB-729

HBV

Capsid Inhibitor (oral)	AB-836
PD-L1 Inhibitor (oral)	AB-101
RNA destabilizer (oral)	AB-161

-19	Mpro small molecule
COVID	Nsp12 viral polymerase

Lead Optimization

IND Enabling

Phase 1

Phase 2

Phase 3

Marketed

AB-729single-ascending dose / multiple-ascending dose

Combo trial (729 + Peg-IFNa-2a + NA)

Combo trial (729 + Vebicorvir + NA)

Combo trial (729 + ATI-2173 + NA)

Combo trial (729 + VTP-300 + NA )*

AB-836single-ascending dose / multiple-ascending dose

NASDAQ: ABUS		5
www.arbutusbio.com	*Clinical trial to initiate in 1H 2022